Tonix Pharmaceuticals Holding Corp. (TNXP) is a biopharmaceutical company based in Chatham, New Jersey, focused on developing innovative therapies for central nervous system disorders and rare diseases. The company is advancing a diversified pipeline of proprietary drug candidates, particularly targeting unmet medical needs in mental health and pain management. With a robust expertise in drug formulation and delivery, Tonix is strategically positioned to capitalize on opportunities in the healthcare market, potentially establishing itself as a leader in the pharmaceutical sector as it navigates its clinical programs toward commercialization. Show more
Location: 26 MAIN STREET, CHATHAM, NJ, UNITED STATES, 07928, Chatham, NJ, 07928, USA | Website: https://www.tonixpharma.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE
Market Cap
190.2M
52 Wk Range
$6.76 - $69.97
Previous Close
$17.24
Open
$17.20
Volume
269,465
Day Range
$16.95 - $18.19
Enterprise Value
13.4M
Cash
190.1M
Avg Qtr Burn
-28.78M
Insider Ownership
0.03%
Institutional Own.
24.91%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
TNX-102 SL (Tonmya™) Details Fibromyalgia | Approved Quarterly sales | |
TNX-4800 Details Lyme Disease | Phase 2/3 Initiation | |
TNX-1900 Details Psychiatric disorder, Binge eating disorder | Phase 2 Data readout | |
TNX-1300 Details Cocaine overdose / intoxication | Phase 2 Data readout | |
TNX-1900 Details Bone disorder, Bone health, Autism spectrum disorders | Phase 2 Data readout | |
TNX-1900 Details Obesity | Phase 2 Data readout | |
TNX-1900 Details Social Anxiety Disorder | Phase 2 Data readout | |
TNX-102 SL Details Acute Stress Reaction | Phase 2 Data readout | |
TNX-102 SL Details COVID-19 | Phase 2 Update | |
TNX-102 SL Details Sleeping disorder, Post-traumatic stress disorder | Phase 2 Update | |
TNX-2900 Details Prader-Willi syndrome | Phase 2 Initiation | |
TNX-102 SL Details Major Depressive Disorder | Phase 2 Initiation | |
TNX-1500 Details Kidney transplantation, Graft-versus-host disease , Hematopoietic cell transplantation | Phase 2 Initiation | |
TNX-801 (recombinant horsepox virus Details Monkeypox, Smallpox | IND Submission | |
TNX-102 SL Details Agitation, Alzheimer's disease | Failed Discontinued | |
TNX-102 SL Details Alcohol dependence | Failed Discontinued | |
TNX-1900 Details Migraines | Failed Discontinued | |
TNX-601 Details Major depressive disorder | Failed Discontinued |
